Lastly, NAFLD was recently correlated with 60% lower omeprazole metabolism (a CYP2C19 substrate)3, and a 28% decrease in CYP2C19 protein58, which is broadly consistent with the expected effect of decreased CYP2C19 mRNA. Here, CYP2C19 is linked to metabolic dysfunction-associated steatotic liver disease.